The changing perspective on chronic insomnia management

Journal of Clinical Psychiatry

Volumn 65, Issue SUPPL. 8, 2004, Pages 20-25

  Krystal, Andrew D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT;

CHRONIC DISEASE; CLASSIFICATION; CLINICAL TRIAL; COGNITIVE THERAPY; HUMAN; INSOMNIA; NOMENCLATURE; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; CLINICAL TRIALS; COGNITIVE THERAPY; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPNOTICS AND SEDATIVES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TERMINOLOGY; TREATMENT OUTCOME;

EID: 3042671653     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Bixler EO, Kales A, Soldatos CR, et al. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry 1979;136:1257-1262
2. Vollrath M, Wicki W, Angst J. The Zurich Study, VIII: insomnia: association with depression, anxiety, somatic syndromes, and course of insomnia. Eur Arch Psychiatry Neurol Sci 1989;239:113-124
3. Zeitlhofer J, Rieder A, Kapfhammer G, et al. Epidemiology of sleep disorders in Austria. Wien Klin Wochenschr 1994;106:86-88
4. Hohagen F, Kappler C, Schramm E, et al. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening: temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 1994;17:551-554
5. National Sleep Foundation. Sleep in America: 1995 Gallup Poll. Available at: http://www.sleepfoundation.org/publications/sleepinamerica1995.cfm
6. Hyyppa MT, Kronholm E, Alanen E. Quality of sleep during economic recession in Finland: a longitudinal cohort study. Soc Sci Med 1997;45: 731-738
7. Chevalier H, Los F, Boichut D, et al. Evaluation of severe insomnia in the general population: results of a European multinational survey. J Psychopharmacol 1999;13:S21-S24
8. Hohagen F, Rink K, Kappler C, et al. Prevalence and treatment of insomnia in general practice: a longitudinal study. Eur Arch Psychiatry Clin Neurosci 1993;242:329-336
9. Hohagen F, Kappler C, Schramm E, et al. Prevalence of insomnia in elderly general practice attenders and the current treatment modalities. Acta Psychiatr Scand 1994;90:102-108
10. Hajak G, Cluydts R, Declerck A, et al. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int Clin Psychopharmacol 2002;17:9-17
11. Cluydts R, Peeters K, de Bouyalsky I, et al. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res 1998;26:13-24
12. Ware JC, Walsh JK, Scharf MB, et al. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol 1997;20:116-125
13. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-199
14. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281:991-999
15. Pasche B, Erman M, Hayduk R, et al. Effects of low energy emission therapy in chronic psychophysiological insomnia. Sleep 1996;19:327-336
16. Friedman L, Brooks JO III, Bliwise DL, et al. Perceptions of life stress and chronic insomnia in older adults. Psychol Aging 1995;10:352-357
17. Diagnostic Classification Steering Committee. International Classification of Sleep Disorders, Revised (ICSD-R): Diagnostic and Coding Manual. Rochester, Minn: American Sleep Disorders Association; 1997
18. Diagnostic Classification Steering Committee. International Classification of Sleep Disorders (ICSD): Diagnostic and Coding Manual. Rochester, Minn: American Sleep Disorders Association; 1990
19. National Institutes of Health Consensus Conference. Drugs and insomnia: the use of medications to promote sleep. JAMA 1984;251:2410-2414
20. Ambien (zolpidem). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2003: 2979-2983
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
22. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999;22:371-375
23. Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy: current status of benzodiazepines. N Engl J Med 1983;309:354-358
24. Ohayon MM, Caulet M, Arbus L, et al. Are prescribed medications effective in the treatment of insomnia complaints? J Psychosom Res 1999;47:359-368
25. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates. Arch Gen Psychiatry 1985;42:225-232
26. Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992;53(12, suppl):34-39
27. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-2177
28. IMS Health. National Prescription Audit. IMS Health Inc; Plymouth Meeting, Pa; March 2002
29. Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002; 22:511-515
30. Espie CA, Brindle S, Tessier S. Supervised cognitive-behavioural therapy for insomnia in general medical practice: preliminary results from the west of Scotland programme. In: Sanavio E, ed. Behavior and Cognitive Therapy Today: Essays in Honour of Hans J. Eysenck: Selected Procceedings of the XXXVII Congress of the European Association for Behavioural and Cognitive Therapies. Amsterdam, the Netherlands: Elsevier; 1998
31. Morin CM, Hauri PJ, Espie CA, et al. Nonpharmacologic treatment of chronic insomnia: an American Academy of Sleep Medicine review. Sleep 1999;22:1134-1156
32. Edinger JD, Sampson WS. A primary care "friendly" cognitive behavioral insomnia therapy. Sleep 2003;26:177-182
33. Zammit G. Insomnia interventions: new ideas for the management of sleep disorders. Clin Geriatr 1999;(July suppl):11-13
34. Ford DE, Cooper-Patrick L. Sleep disturbances and mood disorders: an epidemiologic perspective. Depress Anxiety 2001;14:3-6
35. Gillin JC. Are sleep disturbances risk factors for anxiety, depressive and addictive disorders? Acta Psychiatr Scand Suppl 1998;393:39-43
36. Koren D, Arnon I, Lavie P, et al. Sleep complaints as early predictors of posttraumatic stress disorder: a 1-year prospective study of injured survivors of motor vehicle accidents. Am J Psychiatry 2002;159:855-857
37. Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Intern Med 2002;251:207-216
38. Cricco M, Simonsick EM, Foley DJ. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc 2001;49:1185-1189
39. Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-418
40. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA 1989;262: 1479-1484
41. Chang PP, Ford DE, Mead LA, et al. Insomnia in young men and subsequent depression: the Johns Hopkins Precursors Study. Am J Epidemiol 1997;146:105-114
42. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over six months of nightly treatment: results of a randomized, doubleblind, placebo controlled study in adults with chronic insomnia. Sleep 2003;26:793-799
43. Rybarczyk B, Lopez M, Benson R, et al. Efficacy of two behavioral treatment programs for comorbid geriatric insomnia. Psychol Aging 2002;17:288-298
44. Espie CA, Inglis SJ, Tessier S, et al. The clinical effectiveness of cognitive behaviour therapy for chronic insomnia: implementation and evaluation of a sleep clinic in general medical practice. Behav Res Ther 2001;39:45-60
45. Edinger JD, Wohlgemuth WK, Radtke RA, et al. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA 2001;285:1856-1864
46. Roehrs T, Pedrosi B, Rosenthal L, et al. Hypnotic self administration and dose escalation. Psychopharmacology (Berl) 1996;127:150-154
47. Roehrs T, Bonahoom A, Pedrosi B, et al. Treatment regimen and hypnotic self-administration. Psychopharmacology (Berl) 2001;155:11-17
48. Roehrs T, Bonahoom A, Pedrosi B, et al. Nighttime versus daytime hypnotic self-administration. Psychopharmacology (Berl) 2002;161: 137-142
49. Oswald LM, Roache JD, Rhoades HM. Predictors of individual differences in alprazolam self-medication. Exp Clin Psychopharmacol 1999;7:379-390
50. Hajak G. A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience. Drug Saf 1999;21:457-469
51. Soyka M, Bottlender R, Moller HJ. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry 2000;33:138-141
52. Voderholzer U, Riemann D, Hornyak M, et al. A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. Eur Arch Psychiatry Clin Neurosci 2001;251:117-123
53. Jaffe JH, Bloor R, Crome I, et al. A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction 2004;99:165-173
54. Ancoli-Israel S, Richardson GS, Mangano RM. Long-term exposure to zaleplon is safe and effective in younger-elderly and older-elderly patients with primary insomnia [abstract]. Sleep 2003;26:A77
55. Krystal A, Walsh J, Roth T, et al. The sustained efficacy and safety of eszopiclone over six months of nightly treatment: a placebo-controlled study in patients with chronic insomnia [abstract]. Sleep 2003;26:A310